SESSION DESCRIPTION
Chimeric Antigen Receptor T cell therapies have transformed the outcomes of patients with relapsed and refractory multiple myeloma and its role continues to expand at a rapid pace. This session brings together cutting edge data spanning novel CAR-T constructs, emerging targets beyond BCMA and next-generation platforms designed to improve efficacy and durability.  Presenters will explore how these advances are reshaping treatment paradigms from heavily pretreated myeloma to earlier integration and newly diagnosed treatment settings as the field pushes towards deeper and more durable responses.  Attendees will get insights into latest clinical trial results in this innovative session.
KEYWORDS
Technology and Procedures, Gene Editing, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult